JP2024546195A - １ｈ－フロ［３，２－ｂ］イミダゾ［４，５－ｄ］ピリジン化合物の合成方法 - Google Patents

１ｈ－フロ［３，２－ｂ］イミダゾ［４，５－ｄ］ピリジン化合物の合成方法 Download PDF

Info

Publication number
JP2024546195A
JP2024546195A JP2024539899A JP2024539899A JP2024546195A JP 2024546195 A JP2024546195 A JP 2024546195A JP 2024539899 A JP2024539899 A JP 2024539899A JP 2024539899 A JP2024539899 A JP 2024539899A JP 2024546195 A JP2024546195 A JP 2024546195A
Authority
JP
Japan
Prior art keywords
compound
reaction
added
solvent
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024539899A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023125102A5 (https=
JP2024546195A5 (https=
Inventor
リャン，コンシン
リー，シュアンジャン
フアン，ジュンミン
シー，グオチャン
ドゥアン，ヤヤ
ヤン，プーチャ
Original Assignee
ハンジョウ ハイライトエルエル ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンジョウ ハイライトエルエル ファーマシューティカル カンパニー リミテッド filed Critical ハンジョウ ハイライトエルエル ファーマシューティカル カンパニー リミテッド
Publication of JP2024546195A publication Critical patent/JP2024546195A/ja
Publication of JPWO2023125102A5 publication Critical patent/JPWO2023125102A5/ja
Publication of JP2024546195A5 publication Critical patent/JP2024546195A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
JP2024539899A 2021-12-30 2022-12-19 １ｈ－フロ［３，２－ｂ］イミダゾ［４，５－ｄ］ピリジン化合物の合成方法 Pending JP2024546195A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111658903.5A CN114213424B (zh) 2021-12-30 2021-12-30 一种呋喃[3，2-b]并吡啶衍生物的合成方法
CN202111658903.5 2021-12-30
PCT/CN2022/139966 WO2023125102A1 (zh) 2021-12-30 2022-12-19 1H-呋喃并[3,2-b]咪唑并[4,5-d]吡啶化合物的合成方法

Publications (3)

Publication Number Publication Date
JP2024546195A true JP2024546195A (ja) 2024-12-17
JPWO2023125102A5 JPWO2023125102A5 (https=) 2025-12-26
JP2024546195A5 JP2024546195A5 (https=) 2025-12-26

Family

ID=80707144

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024539899A Pending JP2024546195A (ja) 2021-12-30 2022-12-19 １ｈ－フロ［３，２－ｂ］イミダゾ［４，５－ｄ］ピリジン化合物の合成方法

Country Status (10)

Country Link
US (1) US20250171458A1 (https=)
EP (1) EP4509509A1 (https=)
JP (1) JP2024546195A (https=)
KR (1) KR20240129021A (https=)
CN (2) CN114213424B (https=)
AU (1) AU2022426316A1 (https=)
CA (1) CA3244846A1 (https=)
IL (1) IL313966A (https=)
MX (1) MX2024008276A (https=)
WO (1) WO2023125102A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法
WO2025224600A1 (en) * 2024-04-21 2025-10-30 Biohaven Therapeutics Ltd. Treatment of alpha-synucleinopathies and neuroprotection

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007039146A1 (en) * 2005-09-23 2007-04-12 Smithkline Beecham Corporation 4-carboxy pyrazole derivatives as anti-viral agents
WO2011138657A1 (en) * 2010-05-04 2011-11-10 Glenmark Pharmaceuticals S.A. Aryl substituted olefinic compounds as pde10a inhibitors
JP6057907B2 (ja) * 2011-10-04 2017-01-11 株式会社ヤクルト本社 チアゾリジン誘導体又はその塩を有効成分とする医薬品
CN103450125B (zh) * 2013-07-18 2016-01-13 嘉兴中科化学有限公司 一种5-取代苯丙呋喃-2-羧酸及其衍生物的合成方法
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
CN105418620B (zh) * 2014-09-23 2018-05-04 天津药明康德新药开发有限公司 一种4-(叔丁氧羰基)八氢呋喃并[3,2-b]吡啶-6-羧酸的合成方法
WO2016100349A2 (en) * 2014-12-16 2016-06-23 Rugen Holdings (Cayman) Limited Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists
WO2016196244A1 (en) * 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
CN106432232A (zh) * 2016-09-18 2017-02-22 苏州汉德创宏生化科技有限公司 1‑哌啶‑4‑基‑1,3‑二氢‑咪唑[4,5‑b]吡啶‑2‑酮的合成方法
KR102399848B1 (ko) 2016-10-03 2022-05-19 하이라이트ll 파머슈티컬 (하이난) 컴퍼니, 리미티드 신규한 jak1 선택적 억제제 및 그 용도
CN107216334A (zh) * 2017-06-29 2017-09-29 上海吉尔多肽有限公司 一种6‑氯呋喃[3,2‑b]吡啶的合成方法
CN118619944A (zh) * 2019-06-06 2024-09-10 北京泰德制药股份有限公司 作为atr激酶抑制剂的2,4,6-三取代的嘧啶化合物
KR102785014B1 (ko) 2019-06-06 2025-03-20 항저우 하이라이트엘엘 파마슈티컬 씨오., 엘티디. 푸로이미다조피리딘 화합물의 합성 방법, 푸로이미다조피리딘 화합물의 결정 형태, 및 그의 염의 결정 형태
IL318796A (en) 2019-06-06 2025-04-01 Hangzhou Highlightll Pharmaceutical Co Ltd Method for preparing a furoimidazopyridine compound, polymorph and salt polymorph
CN114213424B (zh) * 2021-12-30 2023-05-26 杭州高光制药有限公司 一种呋喃[3，2-b]并吡啶衍生物的合成方法

Also Published As

Publication number Publication date
CN114213424A (zh) 2022-03-22
WO2023125102A1 (zh) 2023-07-06
CA3244846A1 (en) 2025-06-13
US20250171458A1 (en) 2025-05-29
EP4509509A1 (en) 2025-02-19
CN118679166A (zh) 2024-09-20
KR20240129021A (ko) 2024-08-27
AU2022426316A1 (en) 2024-07-25
MX2024008276A (es) 2024-09-02
IL313966A (en) 2024-08-01
CN114213424B (zh) 2023-05-26

Similar Documents

Publication Publication Date Title
JP2024546195A (ja) １ｈ－フロ［３，２－ｂ］イミダゾ［４，５－ｄ］ピリジン化合物の合成方法
EP2758388B1 (en) New bicyclic dihydroquinoline-2-one derivatives
CN104136437B (zh) N-(5s,6s,9r)-4-(2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶-1-基)哌啶-1-羧酸5-氨基-6-(2,3-二氟苯基)-6,7,8,9-四氢-5h-环庚三烯并[b]吡啶-9-基酯半硫酸盐
CA2908879C (en) Crystal of pyrrole derivative and method for producing the same
KR101808792B1 (ko) 1-[(2-브로모페닐)술포닐]-5-메톡시-3-[(4-메틸-1-피페라지닐)메틸]-1h-인돌 디메실레이트 모노히드레이트의 대규모 생산 방법
WO2018108064A1 (zh) 作为第四代egfr激酶抑制剂的螺环芳基磷氧化合物
RU2737737C2 (ru) АЛЬФА- И БЕТА-НЕНАСЫЩЕННОЕ АМИДНОЕ СОЕДИНЕНИЕ - ПРОИЗВОДНОЕ БЕНЗОТРИАЗОЛА, ПРИМЕНЯЕМОЕ В КАЧЕСТВЕ ИНГИБИТОРА TGF-βRI
HUE026497T2 (en) Methods and intermediates for the preparation of a JAK inhibitor
KR20240018528A (ko) 신규의 염 및 결정
AU2010218667A1 (en) Salt of tetrahydrotriazolopyridine derivative and crystal thereof
JP2020535193A (ja) 結晶のリナグリプチン中間体およびリナグリプチンの調製のためのプロセス
CN118496202A (zh) 生长抑制素受体亚型4(sstr4)激动剂
JP2020536944A (ja) ３−（５−フルオロベンゾフラン−３−イル）−４−（５−メチル−５Ｈ−［１，３］ジオキソロ［４，５−ｆ］インドール−７−イル）ピロール−２，５−ジオンの固体形態
TWI915082B (zh) 用於egfr蛋白降解的化合物及其用途
CN110483520B (zh) 布鲁顿酪氨酸激酶抑制剂的晶型、制备方法及其应用
TW202508560A (zh) 製備ｐ１３ｋ抑制劑之方法
RU2772274C2 (ru) Селективные ингибиторы hdac6, способ их получения и их применение
CN120383608A (zh) 三环化合物的盐、其晶型及其应用
TW202542120A (zh) 化合物及其用途
CN119798222A (zh) 一种阿折地平的制备方法
CN121426813A (zh) 一种irak4降解剂及用途
WO2022111447A1 (zh) 一种btk降解剂的制备方法
CN115611910A (zh) 氨基喹唑啉类化合物的制备方法
CN111362928A (zh) 2,4-二氨基嘧啶衍生物
HK40000494A (en) BENZOTRIAZOLE-DERIVED α AND β UNSATURATED AMIDE COMPOUND USED AS TGF-βR1 INHIBITOR

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251218